Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WILLIAM P WERSCHLER

Allopathic & Osteopathic Physicians Dermatology

NPI
1023119682
CMS profile
182368
Location
SPOKANE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$180,780.39

243 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 4 of 5; records 151–200 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WILLIAM P WERSCHLER

NPI 1023119682 · CMS profile ID 182368

Allopathic & Osteopathic Physicians / Dermatology

SPOKANE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 5; records 151–200 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1023119682?year=2019&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WILLIAM P WERSCHLER, NPI 1023119682, CMS profile ID 182368. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023119682?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). WILLIAM P WERSCHLER, NPI 1023119682, CMS profile ID 182368. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023119682?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
WILLIAM P WERSCHLER, NPI 1023119682, CMS profile ID 182368, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1023119682?year=2019&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

243 matching records · $180,780.39 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 243 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 243.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie, Inc. $265.0705/02/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699197 CMS
AbbVie, Inc. $125.0005/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699207 CMS
GENZYME CORPORATION $31.1105/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694052013 CMS
AbbVie, Inc. $60.0004/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699065 CMS
Celgene Corporation $20.4904/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672776921 CMS
Allergan Inc. $700.0004/16/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671300565 CMS
Novartis Pharmaceuticals Corporation $68.0804/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660202059 CMS
PFIZER INC. $854.4504/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673118509 CMS
PFIZER INC. $3,275.0004/16/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673119333 CMS
Amgen Inc. $14.8904/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663182233 CMS
PFIZER INC. $36.9904/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673116393 CMS
AbbVie, Inc. $18.2004/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699063 CMS
Merz North America, Inc. $984.9704/03/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 689347635 CMS
AbbVie, Inc. $4,025.0004/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699053 CMS
AbbVie, Inc. $4,025.0004/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699221 CMS
AbbVie, Inc. $16.2203/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699055 CMS
AbbVie, Inc. $383.1303/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699059 CMS
AbbVie, Inc. $136.0903/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699219 CMS
AbbVie, Inc. $181.9303/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699223 CMS
AbbVie, Inc. $289.2803/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699057 CMS
DERMIRA, INC. $2,800.0003/27/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703884549 CMS
Celgene Corporation $3.7403/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672757335 CMS
AbbVie, Inc. $19.7403/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699061 CMS
PFIZER INC. $1,036.6903/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673119961 CMS
PFIZER INC. $3,275.0003/22/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673131815 CMS
PFIZER INC. $56.5203/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673119441 CMS
PFIZER INC. $728.0403/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673118411 CMS
Genentech USA, Inc. $12.9403/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681237043 CMS
PFIZER INC. $3,275.0003/11/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673119415 CMS
Galderma Laboratories, L.P. $13.1803/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687726813 CMS
PFIZER INC. $117.2903/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673120521 CMS
Merz North America, Inc. $20.8803/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 689372325 CMS
Merz North America, Inc. $288.1603/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 689373353 CMS
Allergan Inc. $22.1303/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671300559 CMS
Allergan Inc. $150.0003/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671300561 CMS
Celgene Corporation $17.3003/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672739443 CMS
Allergan Inc. $41.6702/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671300539 CMS
Allergan Inc. $139.7502/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671300543 CMS
Allergan Inc. $412.6702/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671300546 CMS
Allergan Inc. $92.3002/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671300549 CMS
Allergan Inc. $3,990.0002/28/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671300553 CMS
Allergan Inc. $76.4202/28/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671300555 CMS
PFIZER INC. $18.9302/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673119255 CMS
Lilly USA, LLC $16.5002/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658223767 CMS
AbbVie, Inc. $18.1802/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699049 CMS
AbbVie, Inc. $14.9002/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699047 CMS
Allergan Inc. $1.0902/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671300537 CMS
Allergan Inc. $7.4702/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671300533 CMS
UCB, Inc. $1,680.0002/11/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688235787 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $1,800.0002/08/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684609729 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $180,780.39 243
PY2020 $83,102.65 135
PY2021 $54,074.84 175
PY2022 $202,423.09 279
PY2023 $297,912.52 288
PY2024 $127,295.28 244
PY2025 $2,888.07 139

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $202,255.36 81
PY2024 Principal investigator $535,642.69 178
PY2023 Recipient $2.02 1
PY2023 Principal investigator $1,097,653.10 181
PY2022 Recipient $7,404.27 2
PY2022 Principal investigator $773,068.07 88
PY2021 Recipient $4,157.88 3
PY2021 Principal investigator $434,980.59 73
PY2020 Recipient $47,971.91 14
PY2020 Principal investigator $485,111.76 143
PY2019 Recipient $27,873.36 39
PY2019 Principal investigator $647,154.43 143

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

81 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $1,627.00 12/25/2025 Non-covered Recipient Entity
PREMIER CLINCIAL RESEARCH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175333020
Principal investigator 1 Janssen Research & Development, LLC $1,601.00 12/19/2025 Non-covered Recipient Entity
PREMIER CLINCIAL RESEARCH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175332977
Principal investigator 1 ABBVIE INC. $1,500.00 12/18/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH LLC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202531318
Principal investigator 1 ABBVIE INC. $1,178.70 12/04/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH LLC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202528774
Principal investigator 1 ABBVIE INC. $2,725.00 11/06/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH LLC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202523261
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $16,151.25 11/06/2025 Non-covered Recipient Entity
Premier Clinical Research
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235994559
Principal investigator 1 ABBVIE INC. $2,800.00 11/05/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH LLC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202521855
Principal investigator 1 Janssen Research & Development, LLC $3,495.00 11/03/2025 Non-covered Recipient Entity
PREMIER CLINCIAL RESEARCH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175333044
Principal investigator 1 Janssen Research & Development, LLC $2,072.00 10/31/2025 Non-covered Recipient Entity
PREMIER CLINCIAL RESEARCH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175333011
Principal investigator 1 Incyte Corporation $1,696.50 10/22/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240577589
Principal investigator 1 Janssen Research & Development, LLC $2,072.00 09/29/2025 Non-covered Recipient Entity
PREMIER CLINCIAL RESEARCH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175332959
Principal investigator 1 Incyte Corporation $95.70 09/18/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240577493
Principal investigator 1 Incyte Corporation $1,187.00 09/18/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240577499
Principal investigator 1 ABBVIE INC. $1,985.25 09/04/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH LLC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202508982
Principal investigator 1 Janssen Research & Development, LLC $1,627.00 09/04/2025 Non-covered Recipient Entity
PREMIER CLINCIAL RESEARCH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175332991
Principal investigator 1 Janssen Research & Development, LLC $3,175.00 08/25/2025 Non-covered Recipient Entity
PREMIER CLINCIAL RESEARCH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175333094
Principal investigator 1 Incyte Corporation $861.30 08/21/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240577487
Principal investigator 1 Janssen Research & Development, LLC $1,913.00 08/01/2025 Non-covered Recipient Entity
PREMIER CLINCIAL RESEARCH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175332997
Principal investigator 1 Janssen Research & Development, LLC $1,627.00 07/28/2025 Non-covered Recipient Entity
PREMIER CLINCIAL RESEARCH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175332984
Principal investigator 1 ABBVIE INC. $148.50 07/17/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH LLC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202498750
Principal investigator 1 ABBVIE INC. $3,400.00 07/10/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
Multicenter Double-Blind Randomized Placebo-controlled Dose-Ranging Phase 2 Active Comparator Study Evaluating the Efficacy and Safety of OnabotulinumtoxinA X for the Treatment of Moderate to Severe Glabellar Lines No dispute reported 06/30/2026 1202497796
Principal investigator 1 ABBVIE INC. $2,628.60 07/08/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH LLC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202497390
Principal investigator 1 Janssen Research & Development, LLC $1,913.00 06/27/2025 Non-covered Recipient Entity
PREMIER CLINCIAL RESEARCH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175333029
Principal investigator 1 Vanda Pharmaceuticals Inc. $2,400.00 06/25/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH LLC
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232945578
Principal investigator 1 Eli Lilly and Company $4,452.10 06/05/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187889482
Principal investigator 1 ABBVIE INC. $2,731.20 06/03/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH LLC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202487617
Principal investigator 1 Incyte Corporation $1,000.00 06/02/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240577565
Principal investigator 1 Incyte Corporation $250.00 06/02/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240577571
Principal investigator 1 Incyte Corporation $1,500.00 06/02/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240577577
Principal investigator 1 Incyte Corporation $550.00 06/02/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240577583
Principal investigator 1 ABBVIE INC. $3,817.20 05/28/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines No dispute reported 06/30/2026 1202486415
Principal investigator 1 Janssen Research & Development, LLC $4,948.00 05/26/2025 Non-covered Recipient Entity
PREMIER CLINCIAL RESEARCH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175333050
Principal investigator 1 Janssen Research & Development, LLC $2,480.00 05/22/2025 Non-covered Recipient Entity
PREMIER CLINCIAL RESEARCH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175332966
Principal investigator 1 ABBVIE INC. $1,314.30 05/07/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH LLC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202483253
Principal investigator 1 Janssen Research & Development, LLC $2,480.00 04/28/2025 Non-covered Recipient Entity
PREMIER CLINCIAL RESEARCH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175333058
Principal investigator 1 Vanda Pharmaceuticals Inc. $2,900.00 04/23/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH LLC
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232945242
Principal investigator 1 ABBVIE INC. $379.35 04/17/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH LLC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202477405
Principal investigator 1 Janssen Research & Development, LLC $2,926.00 04/14/2025 Non-covered Recipient Entity
PREMIER CLINCIAL RESEARCH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175332972
Principal investigator 1 Incyte Corporation $1,000.00 04/08/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240577541
Principal investigator 1 Incyte Corporation $6,600.00 04/08/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240577548
Principal investigator 1 Incyte Corporation $1,500.00 04/08/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240577553
Principal investigator 1 Incyte Corporation $1,500.00 04/08/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240577560
Principal investigator 1 Janssen Research & Development, LLC $2,830.00 04/07/2025 Non-covered Recipient Entity
PREMIER CLINCIAL RESEARCH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175333067
Principal investigator 1 ABBVIE INC. $2,812.20 04/03/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH LLC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202470584
Principal investigator 1 Janssen Research & Development, LLC $415.00 03/31/2025 Non-covered Recipient Entity
PREMIER CLINCIAL RESEARCH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175333006
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $63.40 03/25/2025 Non-covered Recipient Entity
Premier Clinical Research
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting No dispute reported 06/30/2026 1235994563
Principal investigator 1 Incyte Corporation $40.00 03/24/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240577505
Principal investigator 1 Incyte Corporation $10.00 03/24/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240577517
Principal investigator 1 Janssen Research & Development, LLC $5,392.00 03/24/2025 Non-covered Recipient Entity
PREMIER CLINCIAL RESEARCH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175333101
Principal investigator 1 Eli Lilly and Company $11,375.80 03/18/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB No dispute reported 06/30/2026 1187887994
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,350.00 03/14/2025 Non-covered Recipient Entity
Premier Clinical Research
A multi-centre, multi-national clinical study to evaluate the safety and effectiveness of the Essure (Model ESS505) device to prevent pregnancy in women who are seeking permanent contraception No dispute reported 06/30/2026 1225411760
Principal investigator 1 ABBVIE INC. $1,365.60 03/07/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH LLC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202459668
Principal investigator 1 Janssen Research & Development, LLC $3,014.00 03/03/2025 Non-covered Recipient Entity
PREMIER CLINCIAL RESEARCH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175333085
Principal investigator 1 Incyte Corporation $49.66 02/24/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240577530
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,400.00 02/12/2025 Non-covered Recipient Entity
Premier Clinical Research
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting No dispute reported 06/30/2026 1235994565
Principal investigator 1 Janssen Research & Development, LLC $7,011.00 02/07/2025 Non-covered Recipient Entity
PREMIER CLINCIAL RESEARCH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175333036
Principal investigator 1 ABBVIE INC. $2,115.00 02/06/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH LLC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202446988
Principal investigator 1 Incyte Corporation $0.98 02/06/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240553866
Principal investigator 1 Incyte Corporation $1.96 02/06/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240553871
Principal investigator 1 Janssen Research & Development, LLC $3,014.00 01/24/2025 Non-covered Recipient Entity
PREMIER CLINCIAL RESEARCH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175333074
Principal investigator 1 Vanda Pharmaceuticals Inc. $2,900.00 01/22/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH LLC
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232944614
Principal investigator 1 Incyte Corporation $79.65 01/21/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240577595
Principal investigator 1 Incyte Corporation $24.97 01/21/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240577602
Principal investigator 1 Incyte Corporation $323.00 01/21/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240577631
Principal investigator 1 Incyte Corporation $74.00 01/17/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240577607
Principal investigator 1 Incyte Corporation $74.00 01/17/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240577615
Principal investigator 1 Incyte Corporation $23.92 01/17/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240577621
Principal investigator 1 Incyte Corporation $148.00 01/17/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240577627
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $7,850.00 01/16/2025 Non-covered Recipient Entity
Premier Clinical Research
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting No dispute reported 06/30/2026 1235994561
Principal investigator 1 Incyte Corporation $1,634.00 01/10/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240577535
Principal investigator 1 ABBVIE INC. $1,500.00 01/09/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH LLC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202437406
Principal investigator 1 Incyte Corporation $10.00 01/06/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240577512
Principal investigator 1 Incyte Corporation $40.00 01/06/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240577523
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $37,040.15 01/03/2025 Non-covered Recipient Entity
Premier Clinical Research
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 54-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1235994567
Principal investigator 1 ABBVIE INC. $152.55 01/02/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH LLC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202433555
Principal investigator 1 ABBVIE INC. $2,812.20 01/02/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH LLC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202433559
Principal investigator 1 Incyte Corporation $11.45 01/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240553840
Principal investigator 1 Incyte Corporation $16.18 01/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240553844
Principal investigator 1 Incyte Corporation $3.96 01/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240553849
Principal investigator 1 Incyte Corporation $7.08 01/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240553857
Principal investigator 1 Incyte Corporation $61.70 01/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240553861